Hemochromatosis

Hemochromatosis is a multisystem disorder characterized by excessive intestinal absorption of dietary iron, leading to progressive iron deposition in parenchymal tissues such as the liver, heart, pancreas, joints, and pituitary gland. If left untreated, the accumulation of iron induces oxidative stress, tissue injury, and progressive organ damage, presenting as cirrhosis, cardiomyopathy, diabetes, and arthropathy.

Genetic Factors: Primarily caused by autosomal recessive mutations in the HFE gene on chromosome 6 (most commonly C282Y homozygosity, or C282Y/H63D compound heterozygosity). Rarer non-HFE mutations include mutations in transferrin receptor 2 (TFR2), ferroportin (SLC40A1), hemojuvelin (HJV), or hepcidin (HAMP*).

• Secondary Factors: Chronic blood transfusions (hemosiderosis), ineffective erythropoiesis (e.g., thalassemia major, sideroblastic anemia), chronic liver disease (e.g., chronic hepatitis C, alcohol-associated liver disease), and excessive oral iron supplementation.

The primary defect in hereditary hemochromatosis involves deficient production or activity of hepcidin, the master iron-regulatory hormone synthesized by hepatocytes. Hepcidin normally binds to the iron exporter ferroportin on enterocytes and macrophages, inducing its internalization and degradation. When hepcidin is deficient, ferroportin remains active, leading to uncontrolled dietary iron absorption in the duodenum and unregulated iron release from macrophages. This results in saturated transferrin levels and the generation of non-transferrin-bound iron (NTBI). Parenchymal cells take up NTBI rapidly. Inside cells, excess iron promotes the Fenton reaction, producing reactive oxygen species (ROS) that cause lipid peroxidation, membrane damage, cellular death, and subsequent fibrogenesis.

• Prevalence: Hereditary hemochromatosis is one of the most common autosomal recessive disorders in Caucasians of Northern European descent (carrier rate of ~1 in 10; disease prevalence of ~1 in 200 to 1 in 500).
• Age/Gender Distribution: Clinically manifests earlier in males (typically ages 30–50) than in females (typically postmenopausal, ages 50–60), as physiological blood loss from menstruation and pregnancy delays iron accumulation in women.

Homozygosity for the HFE

• C282Y mutation.


• First-degree relative diagnosed with hereditary hemochromatosis.


• Male sex.


• Excessive alcohol consumption (which downregulates hepcidin and worsens liver injury).


• Repeated red blood cell transfusions.

• Vitals: Usually normal, though tachyarrhythmias may be present in advanced cardiac involvement.
• Inspection: Slate-gray or bronze skin pigmentation (most prominent on sun-exposed areas, genitalia, and scars); muscle wasting or scleral icterus in advanced liver disease.
• Palpation: Hepatomegaly (smooth, firm), splenomegaly (in portal hypertension), testicular atrophy, and swelling/tenderness of the MCP joints.
• Auscultation: S3/S4 gallop or bilateral pulmonary crackles in patients with congestive heart failure.

• Test Name: Serum Transferrin Saturation
• Type: Blood Test
• Purpose: Initial screening test for iron overload.
• Expected Findings: Elevated (>45%).
• Interpretation: Values >45% indicate a high likelihood of iron overload and require follow-up ferritin testing.
• Test Name: Serum Ferritin
• Type: Blood Test
• Purpose: Estimate total body iron stores and assess risk of organ damage.
• Expected Findings: Significantly elevated (>300 ng/mL in men, >200 ng/mL in women; often >1000 ng/mL in symptomatic disease).
• Interpretation: Levels >1000 ng/mL correlate strongly with increased risk of liver cirrhosis and fibrosis.

• Genetic Testing

• Expected Findings: Homozygosity for C282Y, or compound heterozygosity for C282Y/H63D.
• Interpretation: Confirms hereditary hemochromatosis type

MRI (T2 or Ferriscan): * Purpose: Non-invasively quantify hepatic and myocardial iron concentration.
Typical Findings: Signal loss (darkening) on T2-weighted sequences proportional to the amount of iron tissue deposition.

• Clinical Importance: Replaces diagnostic liver biopsy in many patients and guides phlebotomy or chelation therapy.

• Typical Findings: Hepatomegaly, increased echogenicity (if concurrent steatosis), or nodularity indicating cirrhosis.


• Clinical Importance: Used for hepatocellular carcinoma (HCC) screening in patients with established cirrhosis.

• Alcoholic Liver Disease: Can cause mild iron overload and elevated ferritin, but transferrin saturation is rarely >50%, and genetic testing is negative.
• Chronic Hepatitis C: Associated with secondary hepatic iron accumulation, but positive HCV RNA tests confirm the diagnosis.
• Thalassemia Major/Intermedia: Presents with severe anemia, ineffective erythropoiesis, and secondary iron overload; diagnosed via hemoglobin electrophoresis.

• Decompensated liver cirrhosis.
• Hepatocellular carcinoma (HCC) (up to 100-fold increased risk in cirrhotic patients).
• Type 2 diabetes mellitus ("bronze diabetes").
• Dilated or restrictive cardiomyopathy and congestive heart failure.
• Hypogonadotropic hypogonadism (due to pituitary iron deposition), leading to erectile dysfunction and osteoporosis.
• Destructive arthropathy (calcium pyrophosphate deposition disease).

• Without Cirrhosis or Diabetes: Patients diagnosed and treated early via phlebotomy have a normal life expectancy.
• With Established Cirrhosis: Significantly reduced survival rates; 10-year survival is approximately 70–80%. Cirrhotic patients remain at high risk for hepatocellular carcinoma even after successful iron depletion.

• Secondary Prevention: Early therapeutic phlebotomy before the onset of organ damage.
• Screening: Targeted screening of first-degree relatives of individuals diagnosed with hereditary hemochromatosis.

The following homeopathic remedies have been historically indicated for symptoms associated with Hemochromatosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Hemochromatosis.